ProShare Advisors
MIRM icon

ProShare Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

ProShare Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$962K Sell
8,217
-596
-7% -$59.8K ﹤0.01% 816
2026
Q1 		$814K Sell
8,813
-961
-10% -$90.4K ﹤0.01% 851
2025
Q4 		$772K Buy
9,774
+1,082
+12% +$77.7K ﹤0.01% 914
2025
Q3 		$637K Sell
8,692
-2,073
-19% -$132K ﹤0.01% 982
2025
Q2 		$548K Sell
10,765
-45
-0.4% -$2K ﹤0.01% 1074
2025
Q1 		$487K Sell
10,810
-2,647
-20% -$125K ﹤0.01% 1116
2024
Q4 		$556K Buy
13,457
+3,227
+32% +$134K ﹤0.01% 1212
2024
Q3 		$399K Buy
10,230
+4,006
+64% +$160K ﹤0.01% 1276
2024
Q2 		$213K Buy
+6,224
New +$163K ﹤0.01% 1500
2024
Q1 		– Sell
-7,074
Closed -$209K – 2016
2023
Q4 		$209K Buy
+7,074
New +$214K ﹤0.01% 1613

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's MIRM Position: Q2 2026 in Review

ProShare Advisors reduced its Mirum Pharmaceuticals (MIRM) stake by 6.8% in Q2 2026, selling an estimated $59.8K and leaving 8,217 shares worth $962K. The position accounts for ﹤0.01% of the portfolio, ranked #816.

ProShare Advisors first reported a position in MIRM in Q4 2023 and has held it in 10 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • ProShare Advisors held 8,217 shares of Mirum Pharmaceuticals worth $962K as of Q2 2026.
  • ProShare Advisors sold 596 Mirum Pharmaceuticals shares in Q2 2026, an estimated $59.8K.
  • Mirum Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #816 holding.
  • ProShare Advisors first reported a position in Mirum Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.